1450 Infinite Drive
31 articles with Rezolute
Rezolute, Inc., a clinical stage biopharmaceutical company dedicated to advancing therapies for rare, metabolic and life-threatening diseases, announced that the Company’s common shares have been approved for listing on the Nasdaq Capital Market.
In an unrelated development, apartnerinitiated Phase 2 development of an undisclosed asset, which triggers $0.5 million milestone payment to XOMA
Rezolute Receives Rare Pediatric Disease Designation for RZ358, Phase 2b Candidate for the Treatment of Congenital Hyperinsulinism, Enabling Eligibility for Priority Review Voucher
Rezolute, Inc., announced that the company has received rare pediatric disease designation from the Food and Drug Administration for RZ358, a potential treatment for congenital hyperinsulinism that is currently being evaluated in a global Phase 2b study.
Rezolute, Inc. Announces Updates to Clinical and Business Operations in Response to COVID-19 Pandemic
Rezolute, Inc., announced an update on the potential impact of the global COVID-19 pandemic on the Company’s clinical and business operations.
REDWOOD CITY, Calif., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “the Company”) (OTCQB:RZLT), today announced the initiation of the RIZE study (RZ358-606), a Phase 2b clinical trial of its lead candidate, RZ358, in patients with congenital hyperinsulinism (CHI). The Company has screened the first patient and expects to make significant enrollment progress to enable attainment of mid-study results over the coming year. “Congenital hyperinsulinism is the most common cau
Rezolute, Inc.(“Rezolute” or “the Company”) (OTCQB:RZLT), today announced an upcoming presentation regarding the company’s clinical development in rare disease at the BIO CEO & Investor Conference 2020, to be held in New York, NY on February 10 – 11. CFO Dr. Keith Vendola, M.D., is scheduled to present on Monday, February 10 at 10 a.m. ET.
12/23/2019Heading into the holidays, there was still plenty of clinical trial news last week. Here’s a look.
Rezolute, Inc. Announces Top-line Results from Phase 1 Trial Evaluating AB101 in Patients with Diabetes
Rezolute, Inc.(“Rezolute” or “the Company”) (OTCQB:RZLT) today announced top-line results from its Phase 1 trial of AB101, an ultra-long acting basal insulin for potential use in patients with type 1 and type 2 diabetes.
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers.
Rezolute, Inc., a biopharmaceutical company specializing in the development of innovative drug therapies for patients with metabolic diseases, announced the appointment of Gil Labrucherie to its Board of Directors where he will serve as Chairman of the Audit Committee.
Rezolute, Inc., announced that senior management will present at the 2019 BIO Investor Forum Conference in San Francisco on Tuesday, October 22, 2019 at 9:00 a.m. PT.
Rezolute Enters Into Common Stock Purchase Agreement for Up to $10M With Lincoln Park Capital Fund, LLC
Proceeds from the Agreement will be used for operations and to advance the development of Rezolute’s product candidates and product collaborations.
Rezolute is responsible for all development, regulatory, manufacturing and commercialization activities under the license.
AntriaBio Announces Selection of Lead Oral Plasma Kallikrein Inhibitor Candidates for the Treatment of Diabetic Retinopathy, Diabetic Macular Edema and Hereditary Angioedema
The two preclinical programs are AB402 for vision-threatening eye complications of diabetes including Diabetic Retinopathy and Diabetic Macular Edema, and AB602, which is being developed to treat Hereditary Angioedema.
AntriaBio And Activesite Pharmaceuticals Announce License And Development Agreement For Plasma Kallikrein Inhibitors
AntriaBio Announces $13 Million Close Of Private Placement Transaction And Plan To Dose First Patient With AB101 This Month
AntriaBio Announces Appointment Of Dr. Hoyoung Huh As Chairman Of Scientific Advisory Board And Business Development